{"article_id": "BIO_q4_2020.txt", "article": ["net sales for the fourth quarter of 2020 were $ 789.8 million , which is a 26.5 % increase on a reported basis , versus $ 624.4 million in q4 of 2019 .", "on a currency neutral basis , sales increased 24.4 % .", "the fourth quarter sales included $ 32 million of damages award related to intellectual property litigation with 10x genomics , covering the period between 2015 and 2018 .", "excluding the $ 32 million , the fourth quarter year - over - year currency neutral revenue growth was 19.4 % .", "the fourth quarter year - over - year revenue growth also benefited from an easy compare of about $ 10 million revenue carryover to q1 of 2020 , related to the december 2019 cyberattack .", "generally , we are seeing most academic and diagnostic labs now running between 70 % and 90 % capacity , which is similar to what we saw in q3 .", "we estimate that covid - 19 related sales were about $ 132 million in the quarter .", "sales of life science group in the fourth quarter of 2020 were $ 428.5 million , compared to $ 242 million in q4 of 2019 , which is a 77.1 % increase on a reported basis and a 73.9 % increase on a currency neutral basis , and it was driven by our pcr product lines , as well as strong performance in the biopharma segment .", "the fourth quarter revenue also included a $ 32 million damages award related to intellectual property litigation .", "excluding that $ 32 million damages award , the currency neutral revenue growth was 60.9 % .", "excluding process media sales and the $ 32 million damages award , the underlying life science business grew 64.6 % on a currency neutral basis versus q4 of 2019 .", "sales of clinical diagnostics products in the fourth quarter were $ 359.6 million compared to $ 379 million in q4 of 2019 , which is a 5.1 % decline on a reported basis and a 6.6 % decline on a currency neutral basis .", "the reported gross margin for the fourth quarter of 2020 was 58.3 % on a gaap basis and compares to 52.9 % in q4 of 2019 .", "the current quarter gross margin benefited mainly from better product mix , lower service costs , higher manufacturing utilization , as well as $ 23 million [ phonetic ] gross margin benefit , associated with the 10x genomics damages award .", "amortization related to prior acquisitions , recorded in cost of goods sold was $ 4.6 million compared to $ 4.5 million in q4 of 2019 .", "sg&a expenses for q4 of 2020 were $ 219.1 million or 27.7 % of sales compared to $ 214.2 million , or 34.3 % in q4 of 2019 .", "total amortization expense related to acquisitions recorded in sg&a for the quarter was $ 2.4 million versus $ 2.1 million in q4 of 2019 .", "research and development expense in q4 was $ 65.8 million or 8.3 % of sales compared to $ 57.1 million , or 9.1 % of sales in q4 of 2019 .", "q4 operating income was $ 175.2 million or 22.2 % of sales , compared to $ 59.2 million or 9.5 % of sales in q4 of 2019 .", "looking below the operating line , the change in fair market value of equity securities holdings added $ 904 million of income to the reported results and this is substantially related to holdings of the shares of sartorius ag .", "during the quarter , interest in other income resulted in a net expense of $ 1 million compared to $ 5.8 million of expense last year .", "our gaap effective tax rate for the fourth quarter of 2020 was 22.2 % compared to 20.9 % for the same period in 2019 .", "reported net income for the fourth quarter was $ 839.1 million , and diluted earnings per share were $ 27.81 .", "in sales , we have excluded the $ 32 million damages award .", "in cost of goods sold , we have excluded $ 8.7 million ip - license costs associated with the damages award .", "$ 4.6 million of amortization of purchased intangibles , and a small restructuring benefit .", "these exclusions moved the gross margin for the fourth quarter of 2020 to a non-gaap gross margin of 58.2 % versus 54.1 % in q4 of 2019 .", "non-gaap sg&a in the fourth quarter of 2020 was 28.2 % versus 31.7 % in q4 of 2019 .", "in sg&a on a non-gaap basis , we have excluded amortization of purchase intangibles of $ 2.4 million , legal related expenses of $ 6.3 million and restructuring and acquisition - related benefits of $ 3.1 million .", "non-gaap r&d expense in the fourth quarter of 2020 was 8.7 % versus 8.2 % in q4 of 2019 .", "the cumulative sum of these non-gaap adjustments result in moving the quarterly operating margin from 22.2 % on a gaap basis to 21.4 % on a non-gaap basis .", "these non-gaap operating margin compares to a non-gaap operating margin in q4 of 2019 of 14.3 % .", "we have also excluded certain items below the operating line , which are the increase in value of the sartorius equity holdings of $ 904.3 million , $ 2.1 million associated with venture investments and $ 3 million of interest income , associated with the 10x damages award .", "our non-gaap effective tax rate for the fourth quarter of 2020 was 24.3 % compared to 17.7 % in 2019 .", "and finally , non-gaap net income for the fourth quarter of 2020 was $ 121 million or $ 4.01 diluted earnings per share , compared to $ 70 million and $ 2.32 per share in q4 of 2019 .", "moving on to the full year results , net sales for the full year of 2020 were $ 2.546 billion on a reported basis , excluding the 10x damages award of $ 32 million , sales were $ 2.514 billion which is 8.9 % growth on a currency neutral basis .", "we estimate that covid - 19 related sales were about $ 313 million .", "sales of life science group for 2020 were $ 1.23108 billion .", "excluding the 10x damages award of $ 32 million , the year - over - year growth was 35 % on a currency neutral basis .", "sales of clinical diagnostics products for 2020 were $ 1.305 billion which is down 7.1 % on a currency neutral basis .", "the full year non-gaap gross margin was 56.9 % compared to 55 % in 2019 .", "full year non-gaap sg&a was 30.9 % compared to 34.4 % in 2019 .", "full year non-gaap r&d was 9.1 % versus 8.5 % in 2019 and full year non-gaap operating income was 17 % compared to 12 % in 2019 .", "lastly , the non-gaap effective tax rate for the full year of 2020 was 24 % , compared to 24.1 % in 2019 .", "the non-gaap effective tax rate for 2020 was consistent with our guidance of 24 % .", "moving on to the balance sheet ; total cash and short - term investments at the end of 2020 was $ 997 million , compared to $ 1.120 billion at the end of 2019 and $ 1.160 billion at the end of the third quarter of 2020 .", "in december , we repaid the $ 425 million of outstanding senior notes .", "year - end inventory decreased by about $ 18 million from the third quarter of 2020 .", "we have a total of $ 273 million available for potential share buybacks .", "full year share buybacks was about 292,000 shares for $ 100 million .", "in 2019 , we purchased about 88,000 shares of our stock for $ 28 million .", "for the fourth quarter of 2020 , net cash generated from operating activities was $ 284.7 million , which compares to $ 159.8 million in q4 of 2019 .", "for the full year of 2020 , net cash generated from operations was $ 575.3 million versus $ 457.9 million in 2019 .", "the adjusted ebitda for the fourth quarter of 2020 was 25.2 % of sales .", "the adjusted ebitda in q4 of 2019 was 18.7 % .", "full year adjusted ebitda , included the sartorius dividend , was $ 546.4 million or about 21.7 % compared to 17.5 % in 2019 .", "net capital expenditures for the fourth quarter of 2020 were $ 39.2 million and full year capex spend was $ 98.9 million .", "depreciation and amortization for the fourth quarter was $ 36.2 million and $ 138.1 million for the full year .", "we project revenues to grow to an overall range of $ 2.75 billion and $ 2.85 billion by the end of 2023 .", "we expect non-gaap gross margin in 2023 to land in a range of 57 % to 57.5 % .", "adjusted ebitda margin should be in the range of 23 % and 24 % , based on top - line growth , productivity improvements , and sg&a leverage .", "the restructuring plan is expected to eliminate a total of approximately 530 positions , approximately 200 positions in manufacturing , and 330 positions across our sg&a and r&d functions .", "and subsequently creation of a total of about 325 new positions , approximately 100 new positions in manufacturing and 225 new positions across sg&a and r&d functions .", "as a result of this restructuring plan , we expect to incur between approximately $ 125 million and $ 130 million in total costs , which we anticipate will consist of approximately $ 86 million cash expenditures , in the form of one - time termination benefits to the affected employees .", "approximately $ 19 million in capital expenses associated with the restructuring plan , and about $ 20 million to $ 25 million in one - time transaction cost .", "we anticipate about $ 80 million to $ 90 million of restructuring charges related to this restructuring plan will be recorded in the first quarter of 2021 , with the balance recorded by the end of 2022 .", "we are guiding a currency neutral revenue growth in 2021 to be between 4.5 % and 5 % .", "we estimate about 10 % to 11 % revenue growth for the diagnostics group .", "full year non-gaap gross margin is projected between 56.2 % and 56.5 % , and full year non-gaap operating margin to be between 16 % and 16.5 % .", "we estimate the non-gaap full year tax rate to be between 24 % and 25 % .", "capex is projected between $ 120 million and $ 130 million and full year adjusted ebitda margin of about 21 % ."], "summary_gold": "q4 non -gaap earnings per share $ 4.01 .<q>q4 earnings per share $ 27.81 .<q>q4 sales $ 789.8 million versus refinitiv ibes estimate of $ 686.8 million .<q>for 2021 , anticipates non -gaap currency - neutral revenue growth of about 4.5 to 5.0 % .<q>sees 2021 estimated non-gaap operating margin of about 16.0 % to 16.5 % .", "summary_pred": "these non-gaap operating margin compares to a non-gaap operating margin in q4 of 2019 of 14.3 % .<q>during the quarter , interest in other income resulted in a net expense of $ 1 million compared to $ 5.8 million of expense last year .<q>looking below the operating line , the change in fair market value of equity securities holdings added $ 904 million of income to the reported results and this is substantially related to holdings of the shares of sartorius ag .<q>excluding that $ 32 million damages award , the currency neutral revenue growth was 60.9 % .<q>our non-gaap effective tax rate for the fourth quarter of 2020 was 24.3 % compared to 17.7 % in 2019 .<q>the cumulative sum of these non-gaap adjustments result in moving the quarterly operating margin from 22.2 % on a gaap basis to 21.4 % on a non-gaap basis .<q>we expect non-gaap gross margin in 2023 to land in a range of 57 % to 57.5 % .<q>the restructuring plan is expected to eliminate a total of approximately 530 positions , approximately 200 positions in manufacturing , and 330 positions across our sg&a and r&d functions .<q>sales of life science group for 2020 were $ 1.23108 billion .<q>the current quarter gross margin benefited mainly from better product mix , lower service costs , higher manufacturing utilization , as well as $ 23 million [ phonetic ] gross margin benefit , associated with the 10x genomics damages award .<q>generally , we are seeing most academic and diagnostic labs now running between 70 % and 90 % capacity , which is similar to what we saw in q3 .<q>we estimate that covid - 19 related sales were about $ 132 million in the quarter .<q>we project revenues to grow to an overall range of $ 2.75 billion and $ 2.85 billion by the end of 2023 .<q>adjusted ebitda margin should be in the range of 23 % and 24 % , based on top - line growth , productivity improvements , and sg&a leverage .<q>on a currency neutral basis , sales increased 24.4 % .<q>in december , we repaid the $ 425 million of outstanding senior notes .", "len_article": 71, "len_summary_gold": 5, "len_summary_pred": 16, "len_sent_scores": 62}